<DOC>
	<DOCNO>NCT00645840</DOCNO>
	<brief_summary>The purpose study determine whether control inflammatory pathway mediate IL-1 beta use IL-1 receptor antagonist anakinra yield measurable decrease expression gene otherwise overexpressed consequence IL-1 beta effect child newly diagnose type 1 diabetes . Ultimately , believe control IL-1 beta pathway associate preserved insulin secretory capacity .</brief_summary>
	<brief_title>Anti-inflammatory Therapy With Anakinra Newly Diagnosed Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>Newly diagnose type 1 diabetes ( ADA criterion ) within 1 week diagnosis . Age 618 year . Males female recruit . Subjects family must English and/or Spanishspeaking . Patients autoimmune condition condition ( include asthma ) necessitate treatment systemic inhaled corticosteroid chronic NSAIDs . Patients receive therapy three month prior enrollment . Hashimoto 's thyroiditis exclusion criterion . Patients active bacterial infection must cure prior entry study protocol . Serum creatinine &gt; 1.5 mg/dL great 1.5x upper limit normal age Serum ALT AST &gt; 3 time upper limit normal lab Platelet count &lt; 100,000/mm3 WBC count &lt; 3,000 cells/mm3 Hemoglobin , Hematocrit Red blood cell count outside 30 % upper low limit normal lab Any medication , opinion investigator , administer immunomodulatory purpose , include limited systemic inhale corticosteroid chronic NSAIDs Subject currently enrol another investigational device drug trial ( ) , subject receive investigational agent ( ) within 28 day baseline visit Treatment past anakinra Patients know hypersensitivity E. coliderived protein , anakinra , component anakinra . Must receive immunosuppressive agent ( include systemic inhale corticosteroid scheduled/chronic NSAIDs ) least three month prior enrollment Known HIVpositive status know history immunodeficiency state . Any mycobacterial disease Active severe infection within 4 week screen visit , screen baseline visit . Severe comorbidities ( congestive heart failure severity , myocardial infarction , cerebrovascular accident transient ischemic attack within 3 month screen visit , unstable angina pectoris , uncontrolled hypertension ( sit systolic BP &lt; 80 mm Hg &gt; 160 diastolic BP &gt; 100 mm Hg ) , oxygendependent severe pulmonary disease , history cancer within 5 year [ resect cutaneous basal squamous cell carcinoma situ cervical cancer ] ) History tuberculosis tuberculosis exposure , chronic hepatitis B hepatitis C , systemic lupus erythematosus . Pregnant lactating female Use live vaccine 90 day prior , study Any condition judge patient 's physician cause clinical trial detrimental patient History noncompliance therapy</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Type 1 diabetes mellitus</keyword>
	<keyword>IL1 beta</keyword>
	<keyword>Anakinra</keyword>
</DOC>